NCM · Biotechnology

GLMD (GLMD) Stock

$4.63 +21.05% NCM: GLMD Healthcare

Valuation

MetricValue
Price$4.63
Market Cap$4.78M
P/E Ratio-0.28
P/B Ratio0.29
P/S Ratio0.00
EPS (TTM)$-2.39
52-Week High$13.20
52-Week Low$3.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-73.68%
ROA-62.04%
ROCE-64.36%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio6.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-33.0M$-18.0M$-7.0M$-6.0M$-9.0M
Net Profit$-32.0M$-18.0M$-7.0M$-8.0M$-10.0M
EPS$-155.84$-88.64$-239.60$-64.64$-19.12
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$37.0M$17.0M$17.0M$19.0M$19.0M
Total Liabilities$6.0M$3.0M$3.0M$2.0M$3.0M
Cash$3.0M$2.0M$3.0M$5.0M$4.0M
Borrowings$0$0$0$0$0

Latest News

Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) InvestorsHub · Jul 16, 2026 Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol PR Newswire · Jul 16, 2026 Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal MT Newswires · Jun 22, 2026 Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition PR Newswire · Jun 22, 2026 Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market PR Newswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-33.0M$-19.0M$-6.0M$-6.0M$-6.0M
Investing Cash Flow$11.0M$18.0M$1.0M$-1.0M$-3.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-4.0M$-1.0M$1.0M$2.0M$-1.0M
Free Cash Flow$-33.0M$-19.0M$-6.0M$-6.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.10
FCF Yield-211.00%
Quick Ratio4.16
Interest Coverage-97.61
Return 1Y-75.07%
Return 3Y-97.05%
Return 5Y-99.89%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About GLMD

GLMD is led by CEO Allen Baharaff, employs 3 people, headquartered in IL, publicly traded since 2014.

GLMD stock trades at $4.63 with a market capitalization of $4.78M. The stock is valued at a price-to-earnings (P/E) ratio of -0.28, price-to-book of 0.29, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.29 and $13.20, and currently trades 64.9% below its 52-week high.

On profitability, GLMD generates a return on equity (ROE) of -73.68%, return on capital employed of -64.36%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides